CA2529244C - Lymphocytes t resistant a la rapamycine et leurs utilisations therapeutiques - Google Patents

Lymphocytes t resistant a la rapamycine et leurs utilisations therapeutiques Download PDF

Info

Publication number
CA2529244C
CA2529244C CA2529244A CA2529244A CA2529244C CA 2529244 C CA2529244 C CA 2529244C CA 2529244 A CA2529244 A CA 2529244A CA 2529244 A CA2529244 A CA 2529244A CA 2529244 C CA2529244 C CA 2529244C
Authority
CA
Canada
Prior art keywords
cells
rapamycin
cell
gvhd
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2529244A
Other languages
English (en)
Other versions
CA2529244A1 (fr
Inventor
Daniel H. Fowler
Unsu Jung
Ronald E. Gress
Bruce Levine
Carl June
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
University of Pennsylvania Penn
Original Assignee
US Department of Health and Human Services
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, University of Pennsylvania Penn filed Critical US Department of Health and Human Services
Publication of CA2529244A1 publication Critical patent/CA2529244A1/fr
Application granted granted Critical
Publication of CA2529244C publication Critical patent/CA2529244C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des méthodes de génération de fonctions Th1/Tc1 et Th2/Tc2 hautement enrichies. En particulier, la génération de ces fonctions est obtenue par l'addition d'un médicament immunodépresseur, la rapamycine ou un composé dérivé de rapamycine. En plus d'une pureté accrue de la fonction lymphocytes T, les lymphocytes T générés dans la rapamycine expriment également des molécules améliorant la fonction lymphocytes T immune telle que CD28 et CD62L. Lesdits sous-ensembles de lymphocytes T fonctionnels générés par rapamycine peuvent avoir une application dans la prévention ou dans le traitement de la réaction de greffe contre hôte GVHD après transplantation de cellules souches hématopoïétiques allogéniques, le traitement de l'auto-immunité ou la thérapie d'infections ou du cancer.
CA2529244A 2003-06-12 2004-06-10 Lymphocytes t resistant a la rapamycine et leurs utilisations therapeutiques Expired - Lifetime CA2529244C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47873603P 2003-06-12 2003-06-12
US60/478,736 2003-06-12
PCT/US2004/018609 WO2005003335A2 (fr) 2003-06-12 2004-06-10 Lymphocytes t resistant a la rapamycine et leurs utilisations therapeutiques

Publications (2)

Publication Number Publication Date
CA2529244A1 CA2529244A1 (fr) 2005-01-13
CA2529244C true CA2529244C (fr) 2014-02-18

Family

ID=33563779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2529244A Expired - Lifetime CA2529244C (fr) 2003-06-12 2004-06-10 Lymphocytes t resistant a la rapamycine et leurs utilisations therapeutiques

Country Status (2)

Country Link
CA (1) CA2529244C (fr)
WO (1) WO2005003335A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503936D0 (en) * 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
GB0603081D0 (en) * 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
WO2010083298A1 (fr) * 2009-01-14 2010-07-22 Health Research Inc. Procédés et compositions contenant des inhibiteurs de la mtor pour améliorer les réponses immunitaires
CN111454903B (zh) * 2020-05-06 2023-10-20 青岛瑞思德生物科技有限公司 免疫细胞体外培养、诱导、激活、冻存方法及其细胞库建立

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038062A2 (fr) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation et utilisation de cellules tc1 et tc2
WO2003004625A1 (fr) * 2001-07-02 2003-01-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Methodes de generation de cellules humaines th2 cd4+ et utilisations associees

Also Published As

Publication number Publication date
WO2005003335A2 (fr) 2005-01-13
WO2005003335A3 (fr) 2005-06-09
CA2529244A1 (fr) 2005-01-13
WO2005003335A9 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
US8075921B2 (en) Rapamycin-resistant T cells and therapeutic uses thereof
US7799350B2 (en) Use of cytokines and mitogens to inhibit graft versus host disease
US20100233192A1 (en) Manufacturing Method of Activated Lymphocytes for Immunotherapy
US20120082687A1 (en) Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
US20200299647A1 (en) New immunoregulatory cells and methods for their production
US20080305079A1 (en) Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
WO2014110020A1 (fr) Compositions et procédés pour l'expansion de cellules souches hématopoïétiques embryonnaires
WO2016179684A1 (fr) Procédé pour la croissance de lymphocytes t régulateurs négatifs doubles
US6803036B1 (en) Use of cytokines, cells and mitogens to inhibit graft versus host disease
WO2016185476A1 (fr) Procédés d'obtention de cellules sanguines mononucléées et leurs utilisations
JP4256431B2 (ja) 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用
Tschan-Plessl et al. Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma
CA2529244C (fr) Lymphocytes t resistant a la rapamycine et leurs utilisations therapeutiques
KR20030081056A (ko) 종양, 감염증 및 자기면역질환의 예방/치료용ｈｌａ일치타인유래의 활성화림프구, 이 림프구를 사용한치료방법, 이 림프구를 주성분으로 하는 제제, 이 제제의제조방법 및 이 제제를 위한 조제용키트
US20240076616A1 (en) Method for t-cell expansion and related medical applications
MacDonald et al. Donor pretreatment with progenipoietin-1 is superior to G-CSF in preventing graft-versus-host disease after allogeneic stem cell transplantation
JP4106488B2 (ja) 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用
US20240108655A1 (en) Methods of producing mixed chimerism after a solid organ transplant
Romano In vitro characterisation and expansion of human regulatory T cells for their in vivo application in the induction of tolerance in haematopoietic stem cell and solid organ transplantation
Einsele Immune Therapy.
Zhang et al. Irinotecan combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice
Degauque et al. TIM-1 PATHWAY CONSTITUTE A NEW “FIRST SIGNAL PATHWAY” FOR T CELL.
Gertow New strategies for allogeneic hematopoietic stem cell transplantation with umbilical cord
Prasad Studies of immune biology of the common marmoset: a novel non-human primate transplant model.
Moodley Studies undertaken to determine the mechanisms underlying transplantation tolerance employing different conditioning regiments in a semiallogeneic murine bone marrow transplantation model.

Legal Events

Date Code Title Description
EEER Examination request